These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 31182249

  • 1. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
    Fujimoto D, Yomota M, Sekine A, Morita M, Morimoto T, Hosomi Y, Ogura T, Tomioka H, Tomii K.
    Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
    [Abstract] [Full Text] [Related]

  • 2. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Fujimoto D, Morimoto T, Ito J, Sato Y, Ito M, Teraoka S, Otsuka K, Nagata K, Nakagawa A, Tomii K.
    Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
    [Abstract] [Full Text] [Related]

  • 3. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T.
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
    Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T.
    Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747
    [Abstract] [Full Text] [Related]

  • 5. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M, Izumo T, Awano N, Kuse N, Inomata M, Jo T, Yoshimura H, Minami J, Takada K, Miyamoto S, Kunitoh H.
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP.
    Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
    Minemura H, Moriya H, Imai H, Sugiyama T, Yamada Y, Higuchi M, Kaira K, Ozaki Y, Kanazawa K, Yokouchi H, Kasai T, Kaburagi T, Suzuki H, Minato K, Shibata Y.
    Thorac Cancer; 2020 Dec; 11(12):3521-3527. PubMed ID: 33044045
    [Abstract] [Full Text] [Related]

  • 9. Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma.
    Baba T, Sakai F, Kato T, Kusumoto M, Kenmotsu H, Sugiura H, Tominaga J, Oikado K, Sata M, Endo M, Yanagawa N, Sasaki S, Iwasawa T, Saito Y, Fujiwara Y, Ohe Y, Yamazaki N, Sakamoto T, Koshiba T, Kuwano K.
    Future Oncol; 2019 Jun; 15(16):1911-1920. PubMed ID: 31020849
    [Abstract] [Full Text] [Related]

  • 10. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F, Hommertgen A, Krisam J, Lasitschka F, Kuon J, Maenz M, Huber PE, König L, Kieser M, Debus J, Thomas M, Rieken S.
    BMC Cancer; 2019 Nov 08; 19(1):1074. PubMed ID: 31703637
    [Abstract] [Full Text] [Related]

  • 11. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T, Kagiyama N, Takano K, Hosoda C, Nishida T, Kawate E, Kobayashi Y, Ishiguro T, Takaku Y, Kurashima K, Yanagisawa T, Takayanagi N.
    Thorac Cancer; 2021 Jan 08; 12(2):153-164. PubMed ID: 33201587
    [Abstract] [Full Text] [Related]

  • 12. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T, Umemura S, Nakamura H, Zenke Y, Udagawa H, Kirita K, Matsumoto S, Yoh K, Niho S, Motoi N, Aokage K, Tsuboi M, Ishii G, Goto K.
    Thorac Cancer; 2019 May 08; 10(5):1285-1288. PubMed ID: 30972962
    [Abstract] [Full Text] [Related]

  • 13. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
    Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, Mouroux J, Schiappa R, Padovani B, Hofman P, Otto J.
    Bull Cancer; 2020 Sep 08; 107(9):946-958. PubMed ID: 32646604
    [Abstract] [Full Text] [Related]

  • 14. Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease.
    Kato M, Shukuya T, Takahashi F, Mori K, Suina K, Asao T, Kanemaru R, Honma Y, Muraki K, Sugano K, Shibayama R, Koyama R, Shimada N, Takahashi K.
    BMC Cancer; 2014 Jul 10; 14():508. PubMed ID: 25012241
    [Abstract] [Full Text] [Related]

  • 15. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R.
    J Cancer Res Clin Oncol; 2019 Feb 10; 145(2):479-485. PubMed ID: 30506406
    [Abstract] [Full Text] [Related]

  • 16. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
    Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K.
    Lung Cancer; 2018 Aug 10; 122():234-242. PubMed ID: 30032838
    [Abstract] [Full Text] [Related]

  • 17. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
    Galli G, Proto C, Cossa M, Valeri B, Sdao S, Signorelli D, Imbimbo M, de Braud F, Garassino MC, Lo Russo G.
    Tumori; 2019 Dec 10; 105(6):NP57-NP62. PubMed ID: 31456503
    [Abstract] [Full Text] [Related]

  • 18. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Kato T, Masuda N, Nakanishi Y, Takahashi M, Hida T, Sakai H, Atagi S, Fujita S, Tanaka H, Takeda K, Satouchi M, Namba Y, Tamura T.
    Lung Cancer; 2017 Feb 10; 104():111-118. PubMed ID: 28212992
    [Abstract] [Full Text] [Related]

  • 19. Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.
    Kobayashi K, Nakachi I, Naoki K, Satomi R, Nakamura M, Inoue T, Tateno H, Sakamaki F, Sayama K, Terashima T, Koh H, Abe T, Nishino M, Arai D, Yasuda H, Kawada I, Soejima K, Betsuyaku T, Keio Lung Oncology Group (KLOG).
    Clin Lung Cancer; 2018 May 10; 19(3):e349-e358. PubMed ID: 29398578
    [Abstract] [Full Text] [Related]

  • 20. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N.
    Lung Cancer; 2019 Jun 10; 132():107-113. PubMed ID: 31097082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.